| Ident. | Authors (with country if any) | Title |
|---|
| 002316 |
Sebastian Paus [Allemagne] ; Hans Michael Brecht [Allemagne] ; Jürgen Köster [Allemagne] ; Gert Seeger [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease |
| 002343 |
Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] | Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor |
| 002467 |
Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study |
| 002477 |
Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] | Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest Tremor and UPDRS part III in Parkinson's disease |
| 002479 |
Carsten Buhmann [Allemagne] ; Alexandra Bussopulos [Allemagne] ; Matthias Oechsner [Allemagne] | Dopaminergic response in Parkinsonian phenotype of Machado-Joseph Disease |
| 002556 |
Ergun Y. Uc [États-Unis] ; Gerald A. Dienel [États-Unis] ; Nancy F. Cruz [États-Unis] ; Sami I. Harik [États-Unis] | β-Adrenergics enhance brain extraction of levodopa |
| 002601 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
| 002626 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
| 002630 |
Susan H. Fox [Royaume-Uni] ; Mark Kellett [Royaume-Uni] ; A. Peter Moore [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia |
| 002666 |
Giulio Cicarelli [Italie] ; Maria Teresa Pellecchia [Italie] ; Giuseppe De Michele [Italie] ; Gilberto Pizzolato [Italie] ; Paolo Barone [Italie] | Paradoxical response to apomorphine in a case of atypical parkinsonism |
| 002672 |
William G. Ondo [États-Unis] ; Joel K. Levy [États-Unis] ; Kevin Dat Vuong [États-Unis] ; Christine Hunter [États-Unis] ; Joseph Jankovic [États-Unis] | Olanzapine treatment for dopaminergic-induced hallucinations |
| 002708 |
Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque] | Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up |
| 002710 |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in Parkinsonian rats |
| 002720 |
J. J. Bob Van Hilten [Pays-Bas] ; Willem-Johan T. Van De Beek [Pays-Bas] ; Johan H. C. Voormolen [Pays-Bas] ; Elmer M. Delhaas [Pays-Bas] | Intrathecal baclofen treatment of dystonia in reflex sympathetic dystrophy |
| 002765 |
J. Carsten Moller [Allemagne] ; Karin Stiasny [Allemagne] ; Volker Hargutt [Allemagne] ; Werner Cassel [Allemagne] ; Heiko Tietze [Allemagne] ; J. Hermann Peter [Allemagne] ; H.-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Evaluation of sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep under dopaminergic medication: A pilot study |
| 002777 |
Guillermo Paradiso [Canada] ; Farooq Khan [Canada] ; Robert Chen [Canada] | Effects of apomorphine on flexor reflex and periodic limb movement |
| 002790 |
| Drugs to treat autonomic dysfunction in Parkinson's disease |
| 002808 |
| DA agonists: ergot derivatives: Bromocriptine |
| 002809 |
| DA agonists: Non-Ergot derivatives: Ropinirole |
| 002810 |
| DA agonists: Non-Ergot derivatives: Pramipexole |
| 002811 |
| DA agonists: Non-Ergot derivatives: Piribedil |
| 002812 |
| DA agonists: Non-Ergot derivatives: Apomorphine |
| 002813 |
| DA agonists: Ergot derivatives: Pergolide |
| 002814 |
| DA agonists: Ergot derivatives: Lisuride |
| 002815 |
| DA agonists: Ergot derivatives: Dihydroergocryptine (DHEC) |
| 002816 |
| DA agonists: Ergot derivatives: Cabergoline |
| 002863 |
| Amantadine and other antiglutamate agents |
| 002880 |
Frithjof Tergau [Allemagne] ; Stephan Wischer [Allemagne] ; Christian Wolf [Allemagne] ; Walter Paulus [Allemagne] | Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine |
| 002881 |
Han-Cheng Wang [Taïwan] ; YOLOUNG HSIEH [Taïwan] | Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy |
| 002884 |
J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis] | Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study |
| 002897 |
F. Tracik [Allemagne] ; G. Ebersbach [Allemagne] | Sudden daytime Sleep onset in Parkinson's disease: Polysomnographic recordings |
| 002919 |
William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie] | Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations |
| 002927 |
Anette Schrag [Royaume-Uni] ; Michael Trimble [Royaume-Uni] | Poetic talent unmasked by treatment of Parkinson's disease |
| 002952 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
| 002966 |
Fabrizio Stocchi [Italie] ; Laura Vacca [Italie] ; Alfredo Berardelli [Italie] ; Francesca De Pandis [Italie] ; Stefano Ruggieri [Italie] | Long-duration effect and the postsynaptic compartment : Study using a dopamine agonist with a short half-life |
| 002A28 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 002A60 |
Eleni C. Maratos [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus) |
| 002A78 |
C. W. Olanow [États-Unis] ; A. H. V. Schapira [Royaume-Uni] ; T. Roth [États-Unis] | Waking up to sleep episodes in Parkinson's disease |
| 002A95 |
L. M. Shulman [États-Unis] ; A. Minagar [États-Unis] ; A. Rabinstein [États-Unis] ; W. J. Weiner [États-Unis] | The use of dopamine agonists in very elderly patients with Parkinson's disease |
| 002B03 |
C. Ramaker [Pays-Bas] ; W. J. T. Van De Beek [Pays-Bas] ; M. J. J. Finken [Pays-Bas] ; B. J. J. Van Hilten [Pays-Bas] | The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications : A systematic review |
| 002B13 |
S. A. Factor [États-Unis] ; D. L. Brown [États-Unis] ; E. S. Molho [États-Unis] | Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease |
| 002B36 |
R. A. Hauser [États-Unis] ; L. Gauger [États-Unis] ; W. M. Anderson [États-Unis] ; T. A. Zesiewicz [États-Unis] | Pramipexole-induced somnolence and episodes of daytime sleep |
| 002B69 |
Robert A. Hauser [États-Unis] ; Mervat N. Wahba [États-Unis] ; Theresa A. Zesiewicz [États-Unis] ; W. Mcdowell Anderson [États-Unis] | Modafinil treatment of pramipexole-associated somnolence |
| 002B87 |
Ruth H. Walker [États-Unis] ; Fabio O. Danisi [États-Unis] ; David M. Swope [États-Unis] ; Robert R. Goodman [États-Unis] ; Isabelle M. Germano [États-Unis] ; Mitchell F. Brin [États-Unis] | Intrathecal baclofen for dystonia: Benefits and complications during six years of experience |
| 002C10 |
Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Endogenous dopaminergic tone and dopamine agonist action |
| 002C43 |
H. A. Jinnah [États-Unis] ; J. P. Sepkuty [États-Unis] ; T. Ho [États-Unis] ; S. Yitta [États-Unis] ; T. Drew [États-Unis] ; J. D. Rothstein [États-Unis] ; E. J. Hess [États-Unis] | Calcium channel agonists and dystonia in the mouse |
| 002C57 |
Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Apomorphine : An underutilized therapy for Parkinson's disease |
| 002C97 |
J. L. Montastruc [France] ; Olivier Rascol [France] ; J.-M. Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 002D27 |
W. Ondo [États-Unis] ; MD [États-Unis] | Ropinirole for restless legs syndrome |
| 002D32 |
A. Schrag [Royaume-Uni] ; L. Schelosky [Allemagne] ; U. Scholz [Allemagne] ; Werner Poewe [Autriche] | Reduction of parkinsonian signs in patients with parkinson's disease by dopaminergic versus anticholinergic single-dose challenges |
| 002D60 |
L. E. Davis [États-Unis] ; J. C. Adair [États-Unis] | Parkinsonism from methanol poisoning : Benefit from treatment with anti-Parkinson drugs |
| 002D76 |
K. R. Müller-Vahl [Allemagne] ; U. Schneider [Allemagne] ; H. M. Emrich [Allemagne] | Nabilone increases choreatic movements in Huntington's disease |
| 002E11 |
M. Merello [Argentine] ; Andrew Lees (neurologue) [Royaume-Uni] ; J. Balej [Argentine] ; A. Cammarota [Argentine] ; R. Leiguarda [Argentine] | GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine |
| 002E21 |
A. S.-I. Pakiam [Canada] ; A. E. Lang [Canada] | Essential palatal tremor : Evidence of heterogeneity based on clinical features and response to sumatriptan |
| 002E24 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
| 002E65 |
E. Grünblatt [Israël] ; S. Mandel [Israël] ; T. Berkuzki [Israël] ; M. B. H. Youdim [Israël] | Apomorphine protects against MPTP-induced neurotoxicity in mice |
| 002E66 |
M. Merello [Argentine] ; J. Balej [Argentine] ; M. Delfino [Argentine] ; A. Cammarota [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine] | Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease |
| 002E67 |
E. Moro [Italie] ; A. Albanese [Italie, Suisse] | Apomorphine and levodopa challenge in patients with a focal midbrain lesion |
| 002E78 |
J.-L. Montastruc [France] ; M. Ziegler [France] ; Olivier Rascol [France] ; M. Malbezin [France] | A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
| 002E80 |
W. Ondo [États-Unis] ; C. Hunter [États-Unis] ; M. Almaguer [États-Unis] ; Joseph Jankovic [États-Unis] | A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease |
| 002F03 |
J. Winkelmann [Allemagne] ; T. C. Wetter [Allemagne] ; K. Stiasny [Allemagne] ; W. H. Oertel [Allemagne] ; C. Trenkwalder [Allemagne] | Treatment of restless leg syndrome with pergolide : An open clinical trial |
| 002F10 |
T. Van Laar [Pays-Bas] ; B. Van Hilten [Pays-Bas] ; C. Neef [Pays-Bas] ; A. W. F. Rutgers [Pays-Bas] ; S. Pavel [Pays-Bas] ; J. A. Bruijn [Pays-Bas] | The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease : A histologic study |
| 002F25 |
A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; F. Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study |
| 002F26 |
Olivier Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 002F74 |
V. P. Calabrese [Canada] ; K. A. Lloyd [Canada] ; P. Brancazio [Canada] ; E. Cefali [États-Unis] ; P. Martin [États-Unis] ; J. Jr Wall [États-Unis] ; D. Sica [États-Unis] | N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism |
| 002F86 |
N. R. Hughes [Royaume-Uni] ; A. T. Mcknight [Royaume-Uni] ; G. N. Woodruff [Royaume-Uni] ; M. P. Hill [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism |
| 003027 |
J. S. Schneider [États-Unis] ; A. Pope-Coleman [États-Unis] ; M. Van Velson [États-Unis] ; F. Menzaghi [États-Unis] ; G. K. Lloyd [États-Unis] | Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys |
| 003030 |
Olivier Rascol [France] ; K. Sieradzan [Royaume-Uni] ; H. Peyro-Saint-Paul [France] ; C. Thalamas [France] ; C. Brefel-Courbon [France] ; J. M. Senard [France] ; P. Ladure [France] ; J. L. Montastruc [France] ; A. Lees [Royaume-Uni] | Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy |
| 003031 |
R. Mielke [Allemagne] ; R. Hilker [Allemagne] ; G. Weber-Luxenburger [Allemagne] ; J. Kessler [Allemagne] ; W.-D. Heiss [Allemagne] | Early-onset cerebellar ataxia (EOCA) with retained reflexes : Reduced cerebellar benzodiazepine-receptor binding, progressive metabolic and cognitive impairment |
| 003044 |
R. K. B. Pearce [Royaume-Uni] ; T. Banerji ; P. Jenner ; C. D. Marsden | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset |
| 003053 |
M. Merello [Argentine] ; A. Cammarota [Argentine] ; M. I. Nouzeilles [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine] | Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test |
| 003079 |
J. D. O'Sullivan [Australie] ; A. J. Hughes [Australie] | Apomorphine-induced penile erections in Parkinson's disease |
| 003080 |
M. Gassen [Allemagne] ; A. Gross [Israël] ; M. B. H. Youdim [Israël] | Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine |
| 003081 |
M. Gassen [Israël] ; A. Gross [Israël] ; M. B. H. Youdim [Israël] | Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine |
| 003155 |
D. Dressler [Allemagne] ; R.-O. Oeljesch Ger [Allemagne] ; E. Rüther [Allemagne] | Severe tardive dystonia: Treatment with continuous intrathecal baclofen administration |
| 003237 |
J. F. Lipinski [États-Unis] ; F. R. Sallee [États-Unis] ; C. Jackson [États-Unis] ; G. Sethuraman [États-Unis] | Dopamine agonist treatment of Tourette disorder in children : Results of an open-label trial of pergolide |
| 003309 |
B. L. Scott [États-Unis] ; R. W. Evans [États-Unis] ; Joseph Jankovic [États-Unis] | Treatment of palatal myoclonus with sumatriptan |
| 003311 |
F. Stocchi [Italie] ; M. F. De Pandis [Italie] ; F. A. Delfino [Italie] ; T. Anselmo [Italie] ; D. Frongillo [Italie] | Transient atrial fibrillation after subcutaneous apomorphine bolus |
| 003376 |
F. Tison [France] ; L. Wiart [France] ; M. Guatterie [France] ; N. Fouillet [France] ; V. Lozano [France] ; P. Henry [France] ; M. Barat [France] | Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease |
| 003377 |
L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; D. De Jong [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis] | Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease |
| 003379 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
| 003386 |
T. E. Eichhorn [Allemagne] ; T. Gasser [Allemagne] ; N. Mai [Allemagne] ; C. Marquardt ; G. Arnold [Allemagne] ; J. Schwarz [Allemagne] ; W. H. Oertel [Allemagne] | Computational analysis of open loop handwriting movements in Parkinson's disease : A rapid method to detect dopamimetic effects |
| 003413 |
L. Smith [Royaume-Uni] ; M. De Salvia [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets |
| 003421 |
T. Van Laar [Pays-Bas] ; C. Neef [Pays-Bas] ; M. Danhof [Pays-Bas] ; K. I. Roon [Pays-Bas] ; R. A. C. Roos [Pays-Bas] | A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease |
| 003463 |
S. Przedborski [Belgique] ; M. Levivier ; C. Raftopoulos ; A. B. Naini ; J. Hildebrand [Belgique] | Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans |
| 003480 |
R. Inzelberg [Israël] ; P. Nisipeanu ; M. J. Rabey ; A. D. Korczyn | Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease |
| 003527 |
S. T. Gancher [États-Unis] ; J. G. Nutt [États-Unis] ; W. R. Woodward | Apomorphine infusional therapy in Parkinson's disease : clinical utility and lack of tolerance |
| 003539 |
G. K. Wenning [Royaume-Uni] ; M. T. O'Connell ; P. N. Patsalos ; N. P. Quinn | A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease |
| 003540 |
A. M. Bonnet [France] ; I. Serre [France] ; R. Marconi [France] ; Yves Agid [France] ; B. Dubois [France] | A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine |
| 003588 |
G. Pezzoli [Italie] ; E. Martignoni ; C. Pacchetti ; V. A. Angeleri ; P. Lamberti ; A. Muratorio ; U. Bonuccelli ; M. De Mari ; N. Foschi ; E. Cossutta ; F. Nicoletti ; F. Giammona ; M. Cansei [Italie] ; G. Scarlato [Italie] ; T. Caraceni ; E. Moscarelli | Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study |
| 003595 |
J. D. Belluzzi [États-Unis] ; E. F. Domino ; J. M. May ; K. S. Bankiewicz ; D. A. Mcafee | N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease |
| 003603 |
S. S. Rich [États-Unis] ; F. Ovsiew | Leuprolide acetate for exhibitionism in Huntington's disease |
| 003685 |
C. A. Hubbard [États-Unis] ; J. M. Trugman | Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists |
| 003733 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 003A74 |
W. Koller ; G. Herbster ; J. Gordon | PHNO, a novel dopamine agonist, in animal models of parkinsonism |
| 003B02 |
W. J. Weiner ; S. A. Factor ; J. Sanchez-Ramos ; J. Berger | A double-blind evaluation of ciladopa in Parkinson's disease |
